Optimising antiresorptive therapies in postmenopausal women: Why do we need to give due consideration to the degree of suppression?

Drugs

Volumn 66, Issue 15, 2006, Pages 1909-1918

  Karsdal, Morten A ^a,b   Qvist, Per ^b   Christiansen, Claus ^a   Tankó, László B ^b  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMG 162; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID; OSTEOPROTEGERIN; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL FEATURE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG INDUCED DISEASE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PREMENOPAUSE; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RANK LIGAND;

ANIMALIA;

EID: 33751079366     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666150-00002     Document Type: Review

References (81)

1. Baron R. Anatomy and biology of bone matrix and cellular elements: primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society for Bone and Mineral Research; 2003: 1-8
2. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption: a hypothesis. Calcif Tissue Int 1981; 33: 349-51
3. Martin TJ. Hormones in the coupling of bone resorption and formation. Osteoporos Int 1993; 3 Suppl. 1: 121-5
4. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000; 289 (5484): 1508-14
5. Garnero P, Sornay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000; 15 (8): 1526-36
6. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999; 84 (7): 2363-8
7. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women: Alendronate Osteoporosis Prevention Study Group. Bone 1999; 24 (3): 237-44
8. Ravn P, Thompson DE, Ross PD, et al. Biochemical markers for prediction of 4-year response in bone mass during bisphosphonate treatment for prevention of postmenopausal osteoporosis. Bone 2003; 33 (1): 150-8
9. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90 (3): 1294-301
10. Hui SL, Slemenda CW, Johnston CC. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 1988; 81 (6): 1804-9
11. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res 2000; 15 (2): 183-7
12. Delmas PD, Li Z, Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 2004; 19 (2): 330-7
13. Boonen S, Laan RF, Barton IP, et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 2005; 16 (10): 1291-8
14. Sarkar S, Reginster JY, Crans GG, et al. Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 2004; 19 (3): 394-401
15. Silverman SL, Moniz C, Andriano K, et al., for the PROOF Study Group. Salmon calcitonin nasal spray prevents vertebral fractures in established osteoporosis: final world wide results of the PROOF trial [abstract]. 26th European Symposium on Calcified Tissues; 1999 May 7-11; Maastricht, 0-26
16. Black DM, Cummings SR, Karpf, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996 Dec 7; 348 (9041): 1535-41
17. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-82
18. Eastell R, Minne H, Sorensen O, et al., for the North American Risedronate Osteoporosis Study Group. Risedronate treatment prevents vertebral and non-vertebral fractures in women with postmenopausal osteoporosis [abstract]. 26th European Symposium on Calcified Tissues; 1999 May 7-11; Maastricht, 0-25
19. Watts N, Hangartner T, Chesnut C, et al., for the North American Risedronate Osteoporosis Study Group. Risedronate treatment prevents vertebral and non-vertebral fractures in women with postmenopausal osteoporosis [abstract]. 26th European Symposium on Calcified Tissues; 1999 May 7-11; Maastricht, 0-24
20. Ettinger B, Black DM, Mitiak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA 1999; 282: 637-45
21. Collette J, Viethel P, Dethor M, et al. Comparison of changes in biochemical markers of bone turnover after 6 months of hormone replacement therapy with either transdermal 17 beta-estradiol or equine conjugated estrogen plus nomegestrol acetate. Gynecol Obstet Fertil 2003; 31 (5): 434-41
22. Fall PM, Kennedy D, Smith JA, et al. Comparison of serum and urine assays for biochemical markers of bone resorption in postmenopausal women with and without hormone replacement therapy and in men. Osteoporos Int 2000; 11 (6): 481-5
23. Rosen CJ, Chesnut CH, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 1997; 82 (6): 1904-10
24. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 2004; 34 (5): 881-9
25. Miller PD, Kendler DL, Garnero P, et al. Once-monthly oral ibandronate effectively normalizes biochemical markers of bone resorption in postmenopausal osteoporosis: MOBILE 2-year analysis [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S289
26. Reginster JY, Wilson KM, Dumont E, et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005; 90 (9): 5018-24
27. Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003; 18 (6): 1051-6
28. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res 2004; 19 (8): 1259-69
29. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350 (12): 1189-99
30. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005; 353 (9): 898-908
31. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346 (9): 653-61
32. Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19 (7): 1059-66
33. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999; 84 (9): 3076-81
34. Harris ST, Eriksen EF, Davidson M, et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2001; 86 (5): 1890-7
35. Evio S, Tiitinen A, Laitinen K, et al. Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis. J Clin Endocrinol Metab 2004; 89 (2): 626-31
36. Garnero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11 (10): 1531-8
37. Garnero P, Sornay-Rendu E, Chapuy MC, et al. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996; 11 (3): 337-49
38. Garnero P, Dargent-Molina P, Hans D, et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos Int 1998; 8 (6): 563-9
39. Chapurlat RD, Garnero P, Breart G, et al. Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. Bone 2000; 27 (2): 283-6
40. Riggs BL, Melton LJ. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 2002; 17 (1): 11-4
41. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18 (2): 75-85
42. Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004; 11 (6 Pt 1): 622-30
43. Bagger YZ, Tanko LB, Alexandersen P, et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003; 33 (3): 301-7
44. Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease. Curr Mol Med 2002; 2 (5): 407-21
45. Fratzl-Zelman N, Valenta A, Roschger P, et al. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 2004; 89 (4): 1538-47
46. Scimeca JC, Franchi A, Trojani C, et al. The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants. Bone 2000; 26 (3): 207-13
47. Quarello P, Forni M, Barberis L, et al. Severe malignant osteopetrosis caused by a GL gene mutation. J Bone Miner Res 2004; 19 (7): 1194-9
48. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397 (6717): 315-23
49. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000; 97 (4): 1566-71
50. Wiktor-Jedrzejczak W, Bartocci A, Ferrante AW, et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A 1990; 87 (12): 4828-32
51. Wiktor-Jedrzejczak W, Urbanowska E, Aukerman SL, et al. Correction by CSF-1 of defects in the osteopetrotic op/op mouse suggests local, developmental, and humoral requirements for this growth factor. Exp Hematol 1991; 19 (10): 1049-54
52. Kornak U, Kasper D, Bosl MR, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell 2001; 104 (2): 205-15
53. Manolios N, Wiseman J, Webb J. Pseudo-avascular necrosis of the hips in a sporadic case of osteopetrosis. Clin Rheumatol 1987; 6 (3): 408-11
54. Bathi RJ, Masur VN. Pyknodysostosis: a report of two cases with a brief review of the literature. Int J Oral Maxillofac Surg 2000; 29 (6): 439-42
55. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20 (3): 345-57
56. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005; 63 (5): 682-9
57. Migliorati CA, Schubert MM, Peterson DE, et al. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer 2005; 104 (1): 83-93
58. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005; 182 (8): 417-8
59. Ficarra G, Beninati F, Rubino I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005; 32 (11): 1123-8
60. Vannucchi AM, Ficarra G, Antonioli E, et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005; 128 (6): 738
61. Robinson NA, Yeo JF. Bisphosphonates: a word of caution. Ann Acad Med Singapore 2004; 33 (4 Suppl.): 48-9
62. Jimenez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Med Oral Pathol Oral Circ Bucal 2005; 10 Suppl. 2: E88-91
63. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62 (5): 527-34
64. Hoff AO, Toth B, Altundag K, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy [abstract]. J Bone Miner Res 2005; 20 Suppl. 1: S55
65. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005; 208: 19-29
66. Orcel P, Denne MA, de Vernejoul MC. Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage. Endocrinology 1991; 128 (3): 1638-46
67. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296 (2): 235-42
68. Coxon FP, Helfrich MH, Larijani B, et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 2001; 276 (51): 48213-22
69. Thompson K, Dunford JE, Ebetino FH, et al. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 2002; 290 (2): 869-73
70. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302 (3): 1055-61
71. Li J, Sato M, Jerome C, et al. Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene. J Bone Miner Metab 2005; 23 Suppl.: 48-54
72. Mashiba T, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23 Suppl.: 36-42
73. Burr DB, Miller L, Grynpas M, et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003; 33 (6): 960-9
74. Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 2001; 69 (5): 281-6
75. Mashiba T, Turner CH, Hirano T, et al. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (5): 524-31
76. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000; 15 (4): 613-20
77. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354 (8): 821-31
78. Capparelli C, Morony S, Warmington K, et al. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. J Bone Miner Res 2003; 18 (5): 852-8
79. Ulrich-Vinther M, Andreassen TT. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. Calcif Tissue Int 2005 Apr; 76 (4): 280-6
80. Dai XM, Zong XH, Akhter MP, et al. Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res 2004; 19 (9): 1441-51
81. Sakagami N, Amizuka N, Li M, et al. Reduced osteoblastic population and defective mineralization in osteopetrotic (op/op) mice. Micron 2005; 36 (7-8): 688-95